title: Dual-isotope SPECT imaging of striatal dopamine: a comparative study between never-treated and haloperidol-treated first-episode schizophrenic patients.
abstract: The aim of this dual-isotope SPECT imaging study was to evaluate striatal dopamine transporter (DAT) and D2 receptor availability in first-episode never-treated and haloperidol-treated schizophrenic patients and whether the availability is associated with psychopathology. Twenty-four inpatients with a first acute schizophrenic episode were enrolled in the study; 12 of these patients were treated with haloperidol for 2 weeks before dual-isotope SPECT was performed, whereas the other 12 patients underwent the SPECT evaluation directly after enrollment. Twelve healthy control persons were also recruited and evaluated with the dual-isotope SPECT protocol. Psychopathology was assessed by the Positive and Negative Syndrome Scale and other scales. D2-radioligand binding did not differ between drug-naïve patients and the control group but was significantly lower in the haloperidol-treated group. DAT availability was also significantly lower in the haloperidol patients than in the other two groups and differed significantly between drug-naïve, positive-syndrome-type patients and healthy controls. The data obtained with the new dual-isotope SPECT technique reveal a direct effect of haloperidol at the D2 and DAT receptor level.
authors.affiliation: Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Munich, Germany.
authors.forename: G J E
authors.initials: GJ
authors.lastname: Schmitt
authors.forename: S
authors.initials: S
authors.lastname: Dresel
authors.forename: T
authors.initials: T
authors.lastname: Frodl
authors.forename: C
authors.initials: C
authors.lastname: la Fougère
authors.forename: R
authors.initials: R
authors.lastname: Boerner
authors.forename: K
authors.initials: K
authors.lastname: Hahn
authors.forename: H-J
authors.initials: HJ
authors.lastname: Möller
authors.forename: E M
authors.initials: EM
authors.lastname: Meisenzahl
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D001549:Benzamides / Q000493:pharmacokinetics; D003342:Corpus Striatum / Q000000981:diagnostic imaging* / Q000187:drug effects; D018492:Dopamine Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D050483:Dopamine Plasma Membrane Transport Proteins / Q000378:metabolism*; D005260:Female; D006220:Haloperidol / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D015609:Organotechnetium Compounds / Q000493:pharmacokinetics; D011485:Protein Binding / Q000187:drug effects; D011569:Psychiatric Status Rating Scales; D011759:Pyrrolidines / Q000493:pharmacokinetics; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D012559:Schizophrenia / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology*; D015899:Tomography, Emission-Computed, Single-Photon; D014326:Tropanes / Q000493:pharmacokinetics; D055815:Young Adult
chemical_list: D001549:Benzamides; D018492:Dopamine Antagonists; D050483:Dopamine Plasma Membrane Transport Proteins; D015609:Organotechnetium Compounds; D011759:Pyrrolidines; D019275:Radiopharmaceuticals; D014326:Tropanes; C104196:technetium Tc 99m TRODAT-1; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide; D006220:Haloperidol
references.citation: J Med Chem. 1997 Jan 3;40(1):9-17
references.pmid: 9016323
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1999 Aug;360(2):109-15
references.pmid: 10494878
references.citation: J Psychopharmacol. 2000;14(4):364-70
references.pmid: 11198054
references.citation: Am J Psychiatry. 2004 Aug;161(8):1496-8
references.pmid: 15285982
references.citation: Psychiatry Res. 2003 Apr 1;122(3):139-52
references.pmid: 12694889
references.citation: J Nucl Med. 1998 Jul;39(7):1138-42
references.pmid: 9669383
references.citation: Eur Arch Psychiatry Clin Neurosci. 2006 Mar;256(2):115-21
references.pmid: 16284713
references.citation: J Psychopharmacol. 2005 Sep;19(5):488-93
references.pmid: 16166186
references.citation: J Med Chem. 1998 Feb 12;41(4):428-36
references.pmid: 9484494
references.citation: Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9235-40
references.pmid: 8799184
references.citation: Am J Psychiatry. 2003 Feb;160(2):303-9
references.pmid: 12562577
references.citation: Arch Gen Psychiatry. 1999 Sep;56(9):781-7
references.pmid: 12884883
references.citation: Am J Psychiatry. 1995 Feb;152(2):173-8
references.pmid: 7840348
references.citation: Eur J Nucl Med. 1999 Apr;26(4):342-7
references.pmid: 10199939
references.citation: Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2569-74
references.pmid: 9122236
references.citation: Eur J Nucl Med. 1998 Jan;25(1):31-9
references.pmid: 9396872
references.citation: Nucl Med Biol. 2001 Jul;28(5):505-8
references.pmid: 11516695
references.citation: Psychiatry Res. 1996 Oct 7;67(3):163-71
references.pmid: 8912956
references.citation: Schizophr Res. 2008 Apr;101(1-3):133-41
references.pmid: 18083348
references.citation: Schizophr Bull. 1987;13(2):261-76
references.pmid: 3616518
references.citation: Arch Gen Psychiatry. 1992 Jul;49(7):538-44
references.pmid: 1352677
references.citation: Brain Res Brain Res Rev. 2000 Mar;31(2-3):342-9
references.pmid: 10719161
references.citation: Brain Res. 1998 Mar 30;788(1-2):215-22
references.pmid: 9555021
references.citation: Nucl Med Biol. 2002 Jul;29(5):561-7
references.pmid: 12088726
references.citation: Psychiatry Res. 2009 Sep 30;173(3):183-9
references.pmid: 19683898
references.citation: Eur J Nucl Med. 1996 Nov;23(11):1527-30
references.pmid: 8854853
references.citation: Am J Psychiatry. 2000 Apr;157(4):514-20
references.pmid: 10739409
references.citation: J Med Chem. 1988 May;31(5):1039-43
references.pmid: 2966245
references.citation: Nucl Med Commun. 2006 Sep;27(9):733-7
references.pmid: 16894328
references.citation: J Cereb Blood Flow Metab. 2000 Mar;20(3):423-51
references.pmid: 10724107
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2000 Mar;361(3):255-64
references.pmid: 10731037
references.citation: Nature. 1995 Nov 9;378(6553):176-9
references.pmid: 7477318
references.citation: Psychopharmacology (Berl). 2002 Jun;162(1):42-9
references.pmid: 12107616
references.citation: J Nucl Med. 1999 Apr;40(4):660-6
references.pmid: 10210226
references.citation: Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8104-9
references.pmid: 10884434
references.citation: Pharmacopsychiatry. 2008 Sep;41(5):169-75
references.pmid: 18763218
references.citation: J Psychopharmacol. 2002 Sep;16(3):200-6
references.pmid: 12236625
references.citation: Schizophr Res. 2001 Oct 1;52(1-2):115-20
references.pmid: 11595398
references.citation: Am J Psychiatry. 1998 Jun;155(6):761-7
references.pmid: 9619147
references.citation: Annu Rev Pharmacol Toxicol. 2001;41:237-60
references.pmid: 11264457
references.citation: Can J Psychiatry. 2005 Jul;50(8):462-9
references.pmid: 16127964
references.citation: Eur J Nucl Med. 2000 Oct;27(10):1518-24
references.pmid: 11083541